Navigation Links
Results From Argos Therapeutics' Arcelis™ Immunotherapy Phase 2 Study for Treatment of Renal Cell Carcinoma (RCC) Accepted for Poster Presentation at Ninth International Kidney Cancer Symposium
Date:9/24/2010

DURHAM, N.C., Sept. 24 /PRNewswire/ -- Argos Therapeutics today announced that results from its Arcelis™ immunotherapy Phase 2 study for the treatment of renal cell carcinoma (RCC) have been accepted for a poster presentation at the Ninth International Kidney Cancer Symposium on Oct. 1-2 in Chicago.

The study is an open-label Phase 2 trial that enrolled 25 patients with newly diagnosed metastatic clear cell RCC.  Post-nephrectomy, subjects received sunitinib and then concomitant AGS-003.  The first endpoint was to evaluate clinical activity as measured by objective tumor response, and the secondary endpoints included safety, clinical activity via estimates of progression free survival, overall survival and assessment of clinical benefit as measured by stable disease, partial response, and CR rates and measurement of immune response.

About the Arcelis™ Technology

Arcelis is Argos' proprietary technology for personalizing RNA-loaded dendritic cell immunotherapies for cancer, HIV and other infectious diseases.  This platform is based on optimizing a patient's own (autologous) dendritic cells to trigger a tumor- or pathogen-specific immune response.  To address the challenge of the unique genetic profile of each patient's disease and the genetic mutations of that disease, Argos loads the autologous dendritic cells with a sample of messenger RNA ("mRNA") isolated from the patient's disease.  Through this process, dendritic cells can potentially prime immune responses to the entire antigenic repertoire, resulting in an immunotherapeutic that is customized to the patient's specific disease.

About Argos Therapeutics, Inc.Argos is an immunotherapy company developing new treatments for cancer, infectious and autoim
'/>"/>

SOURCE Argos Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
5. Tapestry Reports Second Quarter 2007 Results
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)...   NuAire , a manufacturer of ergonomically designed laboratory equipment ... of Japan to sell and service ... . NuAire will utilize its network of sales professionals throughout ... to offer assistance in application use, product benefits and features, ...
(Date:1/14/2014)... Oligomerix, Inc. , a privately held company pioneering the ... and related neurodegenerative disorders, announced today the relocation of ... as of January 15, 2014 and expanded lease ... College. Oligomerix, which is focused on the ...
(Date:1/14/2014)... Evidera , a leading provider of evidence-based solutions for ... Evaluation and Research (CDER), U.S. Food and Drug Administration, ... a patient-reported outcome (PRO) measure in drug development: ... for Measurement of Symptoms of Acute Bacterial Exacerbation of ...
Breaking Medicine Technology:NuAire announces sales and service of Hitachi Koki centrifuges in North America 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 3Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 4
... Vanda Pharmaceuticals Inc. (Nasdaq: VNDA ), announced ... drug designation for tasimelteon, an oral dual melatonin receptor ... Disorder (N24HSWD) in blind individuals with no light perception. ... the Committee for Orphan Medicinal Products (COMP) of the ...
... BrainScope Company, Inc. announced today that it is ... product in development to aid in the assessment of ... the potential to represent a significant advancement in the ... injury (TBI) (including its milder forms commonly referred to ...
Cached Medicine Technology:Vanda Pharmaceuticals Receives Orphan Drug Designation in Europe for tasimelteon 2Vanda Pharmaceuticals Receives Orphan Drug Designation in Europe for tasimelteon 3Vanda Pharmaceuticals Receives Orphan Drug Designation in Europe for tasimelteon 4BrainScope® Prepares to Introduce Ahead™ EU-100 to Aid in Assessment of Head Injury in the United Kingdom 2BrainScope® Prepares to Introduce Ahead™ EU-100 to Aid in Assessment of Head Injury in the United Kingdom 3
(Date:7/9/2014)... of flatulence and have a reputation for being highly toxic, ... is now being being found to offer potential health benefits ... attacks and dementia. A new compound (AP39), designed and made ... future therapies, by targeting delivery of very small amounts of ... , Scientists in Exeter have already found that the ...
(Date:7/9/2014)... A retrospective study conducted by researchers at Tufts University ... adults with intellectual and developmental disabilities, the likelihood of ... dental care increased. The findings, published in the July/August ... help improve interventions designed to address the oral health ... reviewed the dental records of 107 patients at one ...
(Date:7/9/2014)... , , , , ... , , , AUDIO: , ... approximately 30cm from the bullet... , , Click here for ... , , , , , ... , , , , , University of Southampton researchers, with assistance from the Ministry of ...
(Date:7/9/2014)... School of Medicine of the University of Southern ... specific component of the immune system are completely ... infection. The discovery suggests that blocking this immune ... autoimmune and hyper-inflammatory diseases such as rheumatoid arthritis ... published online on June 23 in The ...
(Date:7/8/2014)... The Department of Defense,s Defense Advanced Research Projects ... up to $2.5 million to develop an implantable ... stimulate neurons within the brain to help restore ... research builds on the understanding that memory is ... of the brain encode information, store it and ...
Breaking Medicine News(10 mins):Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 4Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 5Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 6Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 7Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 3
... ... ... Tony Rico has recently been promoted to Senior Vice President of Operations at Jackson ... 1, 2009. , , , , ,"This position has been vacant for a ...
... On Tuesday, October 20, 2009, at 1:00 PM Eastern Time/10:00 AM ... (Nasdaq and MTA: CTIC) management team will host an Annual Meeting of ... WA 98119. The meeting will also be webcast live on CTI,s website ... ...
... being stifled by a U.S. law and successful patent challenges ... this week,s issue of the journal Science . ... of Management at the Georgia Institute of Technology, argue in ... challenges -- a provision of the Hatch-Waxman Act of 1984 ...
... After the Austin City Limits music festival concluded, spa ... Austin, Tx. for the 19th annual International SPA Association ... spa community, participated in educational sessions, learned about the ... The Conference theme, "Simplify," resonated with attendees as ...
... National Awareness Campaign to Combat Breast Cancer has been ... Awareness month. The campaign is led by Princess Hessah bint Trad ... wife of the Custodian of the Two Holy Mosques ... bin Abdulaziz. It officially launched on October 10. , As ...
... scientists interested in finance, entrepreneurships and the chemical sciences are ... Medium Business Webinar for an opportunity to learn about trends ... Scheduled for Thursday, Oct. 22, 2 3 p.m. ... of International eChem and author of the well-regarded ICIS "Chemicals ...
Cached Medicine News:Health News:Jackson & Coker Promotes Tony Rico to Senior VP of Operations 2Health News:Cell Therapeutics, Inc. Annual Meeting of Shareholders Scheduled for Tuesday, October 20, 2009 2Health News:Patent challenges reduce pharmaceutical innovation and productivity, researchers suggest 2Health News:Patent challenges reduce pharmaceutical innovation and productivity, researchers suggest 3Health News:2009 ISPA Conference & Expo Rocks Out With Lance Armstrong in Austin 2
... An APTT-based assay for the detection ... poor anticoagulant response to activated protein C ... an estimation of the anticoagulant function in ... risk associated with inherited and acquired APC ...
Inquire...
Each Uro-Safe® vinyl leg bag is hand-tested for defects through each phase of the manufacturing process and packaged individually in a sterile, easy, peel-open pouch with two latex leg straps....
... valve is enclosed in a ... the valve from being accidentally ... or reclining positions. The valve ... free ensuring uninterrupted flow and ...
Medicine Products: